Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 5Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 1Gastrointestinal 1

Conditions

Severe combined immunodeficiency with sensitivity to ionizing radiation 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × amatuximab × Clear all
NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡